BiotechTube

ISL + ULO + BIC/FTC/TAF

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Conditions

Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Trial Timeline

Apr 14, 2025 → Sep 30, 2031

NCT ID
NCT06891066

About ISL + ULO + BIC/FTC/TAF

ISL + ULO + BIC/FTC/TAF is a phase 2 stage product being developed by Merck for Human Immunodeficiency Virus Type 1 (HIV-1) Infection. The current trial status is active. This product is registered under clinical trial identifier NCT06891066. Target conditions include Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

What happened to similar drugs?

14 of 20 similar drugs in Human Immunodeficiency Virus Type 1 (HIV-1) Infection were approved

Approved (14) Terminated (4) Active (6)
✅lopinavir/ritonavirAbbVieApproved
✅emtricitabine/tenofovir disoproxil fumarateMerckApproved
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
✅3-drug anti-HIV therapy + RaltegravirMerckApproved
✅GardasilMerckApproved
✅RaltegravirMerckApproved
✅RaltegravirMerckApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06891066Phase 2Active

Competing Products

20 competing products in Human Immunodeficiency Virus Type 1 (HIV-1) Infection

See all competitors
ProductCompanyStageHype Score
mRNA-1653ModernaPhase 1
0
mRNA-1653ModernaPhase 1
0
mRNA-1345ModernaPhase 1
0
Influenza vaccine, split inactivatedComac MedicalPhase 1
19
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
40
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
35
DolutegravirShionogiPhase 3
40
GSK1349572 + efavirenzShionogiPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
29
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
29
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
40
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
29
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
29
dolutegravirShionogiPhase 3
40
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
40
GSK1349572 + EfavirenzShionogiPhase 1
29
GSK1349572ShionogiPhase 1
29
GSK1349572 + PlaceboShionogiPhase 2
35
Dolutegravir + MethadoneShionogiPhase 1
29